Targeting cannabinoid receptors in gastrointestinal cancers for therapeutic uses: current status and future perspectives

Pagano, Ester; Borrelli, Francesca

doi:10.1080/17474124.2017.1367663

Cited by 14 publications

(12 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other side, the down-regulation of CB1R has been linked with metastatic CRC [63]. Endogenous and synthetic cannabinoids elicit the suppression of CRC cells proliferation and migration and stimulate apoptosis, via receptor-dependent and independent mechanisms [64]. The intracellular pathways include inhibition of RAS-MAPK and PI3K-AKT axis, cell cycle arrest, down-regulation of anti-apoptotic proteins, increased ceramide synthesis, activation of caspases etc.…”

Section: Gastrointestinal Malignanciesmentioning

confidence: 99%

“…Modification of these compounds taking into account the different anti-cancer potency of various stereoisomers is suggested as a future direction for the development of novel therapies for CRC. Their use for potentiating the effects of standard chemotherapeutics and in preventing adverse side effects like nausea, vomiting, toxicity, pain and loss of appetite needs to be balanced with their known psychotropic effects [64,68]. The anti-cancer potential of the peroxisome proliferator-activated receptor γ (PPARγ) has also been linked with its affinity towards cannabinoids such as THC and JWH-015 in hepatocellular carcinoma in vitro and in vivo [69].…”

Section: Gastrointestinal Malignanciesmentioning

confidence: 99%

See 1 more Smart Citation

The Interplay between Cancer Biology and the Endocannabinoid System—Significance for Cancer Risk, Prognosis and Response to Treatment

Moreno

Čavić

Krivokuća

et al. 2020

Cancers

View full text Add to dashboard Cite

The various components of the endocannabinoid system (ECS), such as the cannabinoid receptors (CBRs), cannabinoid ligands, and the signalling network behind it, are implicated in several tumour-related states, both as favourable and unfavourable factors. This review analyses the ECS’s complex involvement in the susceptibility to cancer, prognosis, and response to treatment, focusing on its relationship with cancer biology in selected solid cancers (breast, gastrointestinal, gynaecological, prostate cancer, thoracic, thyroid, CNS tumours, and melanoma). Changes in the expression and activation of CBRs, as well as their ability to form distinct functional heteromers affect the cell’s tumourigenic potential and their signalling properties, leading to pharmacologically different outcomes. Thus, the same ECS component can exert both protective and pathogenic effects in different tumour subtypes, which are often pathologically driven by different biological factors. The use of endogenous and exogenous cannabinoids as anti-cancer agents, and the range of effects they might induce (cell death, regulation of angiogenesis, and invasion or anticancer immunity), depend in great deal on the tumour type and the specific ECS component that they target. Although an attractive target, the use of ECS components in anti-cancer treatment is still interlinked with many legal and ethical issues that need to be considered.

show abstract

Section: Gastrointestinal Malignanciesmentioning

confidence: 99%

Section: Gastrointestinal Malignanciesmentioning

confidence: 99%

The Interplay between Cancer Biology and the Endocannabinoid System—Significance for Cancer Risk, Prognosis and Response to Treatment

Moreno

Čavić

Krivokuća

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

“…For instance, treatment with the nonselective CB 1 /CB 2 agonist HU210 or CBD reduced the development of precancerous lesions in mouse models of chemically induced CRC [61,62]. Similar results were obtained by increasing the levels of ECs by way of inhibiting the degrading enzymes FAAH and MGL [61,63]. However, another study reported that blockade of ECS signaling by application of the CB 1 antagonist SR141716 also reduced preneoplastic lesion formation in a mouse model of CRC [64].…”

Section: Cannabinoids and Crcmentioning

confidence: 48%

“…In this context, it should be mentioned that a combination of THC with CBD effectively increased cell death and migration of multiple myeloma cell lines in synergy with carfilzomib, a proteasome inhibitor, used for the treatment of multiple myeloma [95]. The topic of cannabinoid therapy in CRC has also been addressed in a recent editorial [63].…”

Section: Are Cannabinoids a Therapeutic Option For Inflammation And Nmentioning

confidence: 99%

Medical Cannabis and Cannabinoids: An Option for the Treatment of Inflammatory Bowel Disease and Cancer of the Colon?

Grill

Hasenoehrl

Storr

et al. 2018

Med Cannabis Cannabinoids

View full text Add to dashboard Cite

In the past few years, we have witnessed a surge of new reports dealing with the role of cannabinoids, synthetic as well as herbal, in the mechanisms of inflammation and carcinogenesis. However, despite the wealth of in vitro data and anecdotal reports, evidence that cannabinoids could act as beneficial drugs in inflammatory bowel disease (IBD) or in neoplastic development of the human gastrointestinal tract is lacking. Some insight into the effects of medical Cannabis (usually meaning dried flowers) and cannabinoids in IBD has been gained through questionnaires and small pilot studies. As to colorectal cancer, only preclinical data are available. Currently, Δ⁹-tetrahydrocannabinol (THC) and its synthetic forms, dronabinol and nabilone, are used as an add-on treatment to alleviate chronic pain and spasticity in multiple sclerosis patients as well as chemotherapy-induced nausea. The use of medical Cannabis is authorized only in a limited number of countries. None of the mentioned substances are currently indicated for IBD. This review is an update of our knowledge on the role of cannabinoids in intestinal inflammation and carcinogenesis and a discussion on their potential therapeutic use.

show abstract

“…Since the beginning of the first phytocannabinoids characterisation in the 20 th century, see Grotenhermen (2004), and the first studies using tetrahydrocannabinol and cannabidiol, we faced a boost in research involving cannabinoids. With the use of medicinal cannabis being legalised in a growing number of countries, several studies in different health areas have been conducted such as in inflammatory diseases, see e.g., Hasenoehrl et al (2017), neurological disorders or related symptoms, see Solimini et al (2017); Pertwee (2012), cancer, see Pagano and Borrelli (2017); Naderi et al (2018); Pastor et al (2004); Milano et al (2017) and cardiovascular diseases, see Mendizabal and Adler-Graschinsky (2007).…”

Section: Introductionmentioning

confidence: 99%

Towards Automated Management and Analysis of Heterogeneous Data within Cannabinoids Domain

Koga¹,

Spichkova

Mantri

2019

Proceedings of the 14th International Conference on Evaluation of Novel Approaches to Software Engineering

View full text Add to dashboard Cite

Cannabinoid research requires the cooperation of experts from various field biochemistry and chemistry to psychological and social sciences. The data that have to be managed and analysed are highly heterogeneous, especially because they are provided by a very diverse range of sources. A number of approaches focused on data collection and the corresponding analysis, restricting the scope to a sub-domain. Our goal is to elaborate a solution that would allow for automated management and analysis of heterogeneous data within the complete cannabinoids domain. The corresponding integration of diverse data sources would increase the quality and preciseness of the analysis. In this paper, we introduce the core ideas of the proposed framework as well as present the implemented prototype of a cannabinoids data platform. a a Preprint.

show abstract

Targeting cannabinoid receptors in gastrointestinal cancers for therapeutic uses: current status and future perspectives

Cited by 14 publications

References 26 publications

The Interplay between Cancer Biology and the Endocannabinoid System—Significance for Cancer Risk, Prognosis and Response to Treatment

The Interplay between Cancer Biology and the Endocannabinoid System—Significance for Cancer Risk, Prognosis and Response to Treatment

Medical Cannabis and Cannabinoids: An Option for the Treatment of Inflammatory Bowel Disease and Cancer of the Colon?

Towards Automated Management and Analysis of Heterogeneous Data within Cannabinoids Domain

Contact Info

Product

Resources

About